Bora, a contract development and manufacturing organization (CDMO) that specializes in complex modified release (MR) products and solvent production, has announced the opening of its first North American office in Delaware, U.S.
The Asia-Pacific (APAC)-headquartered CDMO, which has invested over $60 million in acquiring world class facilities in recent years, has established the office as part of its two-year plan to invest in the North American market.
Commenting on the new office, Bobby Sheng, CEO at Bora Pharmaceuticals, said: “Opening an office on the East coast of the U.S., is a significant milestone for our organization and signals our continued commitment to the region.
“The office is one phase of our expansion plans, as we continue to explore acquisition opportunities in the market. It will not only support our own future growth strategy but also allows us to better support our growing client base, as companies across the U.S. continue to outsource their most complex oral solid dose (OSD) projects to Bora.”
Sheng continues: “It’s an extremely exciting time for Bora, and I am looking forward to establishing further fruitful and collaborative partnerships in the U.S.”
Bora appointed its U.S. director of business development, Louis Weber, in late 2018 and he will lead the company’s growth strategy across North America and Europe.
Previously a senior director of business development at Halo Pharma (now acquired by Cambrex), Weber has almost 20 years’ experience in the pharmaceutical sector and sits at the forefront of Bora’s growth strategy.
Weber added: “As an industry, we are seeing a rising demand for large scale manufacturing projects that have the same diverse and challenging requirements of niche drug products. This is what attracted me to Bora, as its sweet spot is providing complex dosage forms on a large commercial scale.
“I am eager to build an ambitious team in North America that is inspired to continue delivering smart, solution-driven support for our clients and their complex MR projects.”
Bora offers a broad range of technologies across its multiple sites, from small scale R&D capabilities to large scale manufacturing services. The company also provides packaging, distribution, tech transfer, stability studies, and product life cycle management capabilities for clinical trial and commercial projects.
The publicly listed company is one of the largest CDMOs in Asia and has strong financial foundations in place thanks in-part to core shareholders including, UMC and Taishin Financial Holdings, one of the largest banks in Taiwan.
This announcement follows the recent reports of Bora’s fifth successful FDA inspection with zero 483 observations at its export manufacturing facility in Zhunan, Taiwan.
Bora will be exhibiting at CPhI Worldwide alongside the Taiwan Pharmaceutical Alliance.
